According to the results of the second phase of the study, the combination of standard-care chemotherapy drug azacitidine and the immune checkpoint inhibitor nivolumab ( nivolumab) waxay muujisay in heerka jawaabta iyo soo noqoshada bukaanada qaba cudurka leukemia ee ba'an ee soo noqnoqda ama soo noqnoqda ( AML ) Heerka badbaadada guud waa mid dhiirigelin leh.
Daraasadu waxay raacday 70 bukaan ah. Celcelis ahaan 2 xariiq oo daaweyn ah, dib u soo noqoshada AML ayaa soo warisay heerka jawaabta guud ee 33% iyo heerka jawaabta oo dhameystiran oo ah 22%. Isku darka daawada ayaa si gaar ah waxtar ugu leh bukaanada aan horey u helin wakiilada hypomethylation (HMA) sida azacitidine ama decitabine, wadarta guud ee waxtarka leh ee bukaanadani waa 52%.
Baarayaasha ayaa sheegay in shaybaarka lafaha la uruuriyay ka hor daaweynta ay muujisay in inta jeer ee saadaasha lafaha lafaha CD3 iyo unugyada CD8 ka hor daaweynta ay ka sareeyeen. Gaar ahaan, CD3 waxay umuuqataa inay leedahay xasaasiyad sare iyo heer gaar ahaaneed si loo saadaaliyo jawaabta, taasoo muujineysa in loo isticmaali karo inay tahay biomarker lagu kalsoonaan karo oo loogu talagalay xulashada bukaanada daaweyntan isku dhafan. “
Daaweynta waxaa ka mid ah cirbadaha xididka ama subcutaneous ee azacitidine iyo cirbadeynta xididka ee nivolumab. In kasta oo bukaanada badankood si guul leh loo daweeyey, 11% bukaanada weli waxay leeyihiin waxyeelo halis ah ama nolosha halis gelin karta. Badbaadada guud ee dhammaan bukaanada waxay ahayd 6.3 bilood. Heerka badbaadada ee bukaanka qaba soo noqoshada ugu horreysay waxay ahayd 10.6 bilood, taas oo ahayd laba jeer heerka badbaadada ee lagu arkay azacitidine oo keliya bukaannada la midka ah ee MD Anderson.
Cilmi-baare Daver wuxuu sheegay in daraasadda wajiga III ee daraasaddan la kala-soocay ay socoto, waxaana aaminsanahay in hirgelinta bukaan-socod eegtada bukaan-socodka iyo difaaca jirka ee xulashada bukaannada ay ka dhalan karto horumar dheeri ah oo ku saabsan noocyada daaweynta ee AML.
https://medicalxpress.com/news/2018-11-combination-chemotherapy-immunotherapy-effective-phase.html
